Bispecific recombinant protein and use thereof

US11518810B2 · kind B2 · utility

Assignee

• SHANGHAI JMT-BIO TECHNOLOGY CO., LTD. · CN

Inventors

• Liping SONG · Shanghai, CN
• Xiaotian Cui · Shanghai, CN
• Jian Wang · Newton, US
• Haixiang WU · Shanghai, CN
• Jiana JIA · Shanghai, CN
• Yi FAN · Shanghai, CN
• Ganliang ZHANG · Shanghai, CN
• Tao Li · San Diego, US
• Hong Xu · San Diego, US
• Yisha SHE · Shanghai, CN
• Kai Long · Shanghai, CN

Key dates

• Filing date: May 8, 2018
• Grant date: Dec 6, 2022
• Expiry date: Mar 12, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRPα. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRPα, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRPα comprises a SIRPα extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.